Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease

Baeyens, Vincent; Bron, Alain M.; Baudouin, Christophe

doi:10.1016/j.jfo.2011.07.017

Cited by 52 publications

(76 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Twenty trials were reported as being double-masked (Baeyens 2012; Bron 1998a; Christensen 2009; Cohen 2014; Johnson 2008; Nelson 1988; Tomlinson 2013), single-masked (Foley-Nolan 1995), masked (Simmons 2007), masked-observer (Lee 2011) or investigator-masked trials (Aguilar 2014; Benelli 2010; Brodwall 1997; Bron 1998b; Donshik 1998 Trial 2; Donshik 1998 Trial 3; Khanal 2007; Kislan 2008; Simmons 2004a; Xiao 2008), but insufficient details were provided as to how masking was performed. Iester 2000 did not report masking.…”

Section: Resultsmentioning

confidence: 99%

Over the counter (OTC) artificial tear drops for dry eye syndrome

Pucker

Nichols

2016

Cochrane Database of Systematic Reviews

126

124

View full text Add to dashboard Cite

Background-Over the counter (OTC) artificial tears historically have been the first line of treatment for dry eye syndrome and dry eye-related conditions like contact lens discomfort, yet currently we know little regarding the overall efficacy of individual, commercially available artificial tears. This review provides a much needed meta-analytical look at all randomized and quasi-randomized clinical trials that have analyzed head-to-head comparisons of OTC artificial tears. Objectives-To evaluate the effectiveness and toxicity of OTC artificial tear applications in the treatment of dry eye syndrome compared with another class of OTC artificial tears, no treatment, or placebo. Search methods-We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2015, Issue 12), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to December 2015), EMBASE (January 1980 to December 2015), Latin American and Caribbean Health Sciences (LILACS) (January 1982 to December 2015), the ISRCTN registry (www.isrctn.com/ editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en)

show abstract

Section: Resultsmentioning

confidence: 99%

Over the counter (OTC) artificial tear drops for dry eye syndrome

Pucker

Nichols

2016

Cochrane Database of Systematic Reviews

126

124

View full text Add to dashboard Cite

show abstract

“…Tears of keratoconjunctivitis sicca and Sjögren's patients show higher values (343 mosmol/L) [56]. Therefore these patients welcome hypotonic eye drops [57].…”

Section: Osmotic Value Of the Preparationmentioning

confidence: 92%

“…Apart from the polymers mentioned in Table 10.6 some authorised medicines contain other viscosity enhancing agents such as dextran, hydroxyethylcellulose, hyaluronic acid and hydroxypropylguar gum (HP-guar; Systane®) [36,37,57]. Hyaluronic acid possesses good adhesive properties.…”

Section: Viscosity Enhancing Polymersmentioning

confidence: 99%

Eye

Ludwig

Reimann²

2015

Practical Pharmaceutics

View full text Add to dashboard Cite

“…69 Clinical studies have confirmed the efficacy of topical application of hyaluronic acid to confer both subjective and objective symptomatic relief in patients with dry eye, with a good safety profile. [70][71][72] Apart from subjective and objective symptom improvement in patients with dry eye, long-term treatment with hyaluronic acid reduced ocular surface damage in patients with moderate to severe dry eye. 73 Hydroxypropyl methylcellulose has also been found to be effective in improving dry eye symptoms in patients with and without Sjögren dry eye, with a significant improvement in the conjunctival and corneal staining scores and breakup times.…”

Section: Rewetting or Comfort Agentsmentioning

confidence: 99%

Dry Eye Treatment Based on Contact Lens Drug Delivery: A Review

Guzmán-Aránguez

Fonseca

Carracedo

et al. 2016

Eye &Amp; Contact Lens: Science &Amp; Clinical Practice

View full text Add to dashboard Cite

Dry eye disease affects a substantial segment of the word population with increasing frequency. It is a multifactorial disease of the ocular surface and tear film, which causes ocular discomfort, visual disturbances, and tear instability with potential damage to the cornea and conjunctiva. Because of its multifactorial etiology, the use of different pharmacological treatment for dry eye treatment has been proposed, which include anti-inflammatory molecules, lubricants or comfort agents, and secretagogues. However, in some cases these pharmacological approaches only relieve symptoms temporarily, and consequently, eye care professionals continue to have difficulties managing dry eye. To improve pharmacological therapy that allows a more efficient and long-term action, effective ocular drug delivery of the currently available drugs for dry eye treatment is required. Contact lenses are emerging as alternative ophthalmic drugs delivery systems that provide an increased residence time of the drug at the eye, thus leading to enhanced bioavailability and more convenient and efficacious therapy. In this article, we reviewed the different techniques used to prepare contact lens-based drug delivery systems and focused on articles that describe the delivery of compounds for dry eye treatment through contact lenses.

show abstract

Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease

Cited by 52 publications

References 17 publications

Over the counter (OTC) artificial tear drops for dry eye syndrome

Over the counter (OTC) artificial tear drops for dry eye syndrome

Eye

Dry Eye Treatment Based on Contact Lens Drug Delivery: A Review

Contact Info

Product

Resources

About